苯那普利对尿毒症难治性高血压及其血浆肾素-血管紧张素的影响

Using Benazepril for Antihypertensive Therapy in Uremic Patients with Refractory Hypertension

选择尿毒症维持性血液透析并经开博通加心痛定治疗无效的高血压患者28例,改用苯那普利(洛丁·新)加硝苯吡啶治疗6周后,血压由治疗前的(22.6±2.7)/(13.6±1.8)kPa降为治疗后的(20.1±2.8)/(12.0±2.O)kPa(<O.01)。总有效率为84.6％,显效率为73.1％。其降压作用与血浆肾素-血管紧张素水平无关。除2例因血压明显降低退出治疗外,无明显副作用,提示洛丁新对于开博通治疗无效的尿毒症难治性高血压仍然有效,且洛丁新加心痛定的治疗效果更好。

Twenty-eight chronic uremic patients with refractory hypertension under supportive hemodialysis were treated by the combination of captopril and nifedipine and had no improvement at all. They were treated then by benazepril and blood pressure dropped from(22. 6±2. 7)/(13. 6±1. 8)kPa to(20. 1± 2. 8)/(12. 0 ± 2. 0)kPa(P<0. 01). The total effectiveness rate was 84. 6%. The obvious effectiveness rate was 73. 1%. The mechanism of reducing blood pressure had no association with the plasma levels of renin-angiotensin. There were no severe side effects. It was suggested that benazepril was still effective for refractory uremic hypertension which had been treated by captopril without any effect.